Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria (StepUp)
Assessment of Initial Oral Vinorelbine Dosing Schedules Used for the Treatment of Advanced Non-small-cell Lung Cancer and Metastatic Breast Cancer in Clinical Routine in Germany and Austria (StepUp)
Sponsor: Pierre Fabre Pharma GmbH
Listed as NCT02619929, this observational or N/A phase trial focuses on Breast Cancer and Non-Small-Cell Lung Cancer and remains completed. Sponsored by Pierre Fabre Pharma GmbH, it has been updated 10 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2018 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — Mar 2018 [monthly]
Recruiting NA
-
Jan 2017 — Dec 2017 [monthly]
Recruiting NA
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pierre Fabre Pharma GmbH
- Winicker Norimed GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Altötting, Germany , Amberg, Germany , Bad Nauheim, Germany , Ballenstedt, Germany , Berlin, Germany , Bielefeld, Germany , Braunau am Inn, Austria , Chemnitz, Germany , Cologne, Germany and 46 more locations